Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Sarepta Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::2216555822.png) @Sarepta Sarepta Therapeutics

Sarepta Therapeutics posts on X about  the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::2216555822/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2216555822/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX +31%
- X Months XXXXXX +491%
- X Year XXXXXX -XX%

### Mentions: X [#](/creator/twitter::2216555822/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2216555822/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XX +21%
- X Months XX +94%
- X Year XX +175%

### Followers: XXXXX [#](/creator/twitter::2216555822/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2216555822/c:line/m:followers.svg)

- X Week XXXXX +1.80%
- X Month XXXXX +3.50%
- X Months XXXXX +7.50%
- X Year XXXXX +13%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::2216555822/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2216555822/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::2216555822/influence)
---

**Top accounts mentioned or mentioned by**
[@yachmod](/creator/undefined) [@cphilstrom](/creator/undefined) [@genbio](/creator/undefined) [@parentprojectmd](/creator/undefined) [@jmaraganore](/creator/undefined) [@alexwestchester](/creator/undefined) [@yasiejko](/creator/undefined) [@marksharkking](/creator/undefined) [@mdaorg](/creator/undefined) [@duncanburnsma](/creator/undefined) [@yaireinhorn](/creator/undefined) [@stock_truth](/creator/undefined) [@yusufhameed](/creator/undefined) [@pharmacompass](/creator/undefined) [@superduperdrugs](/creator/undefined) [@defeatduchenne](/creator/undefined) [@paulmarganski](/creator/undefined) [@cureduchenne](/creator/undefined) [@zinselmeyerb](/creator/undefined) [@rwarner42](/creator/undefined)
### Top Social Posts [#](/creator/twitter::2216555822/posts)
---
Top posts by engagements in the last XX hours

"News: The U.S. FDA granted Platform Technology Designation to SRP-9003 Sareptas investigational gene therapy for the treatment of LGMD type 2E/R4. This is one of the first programs to receive the technology designation. Read more at"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1930272306384793816) 2025-06-04 14:35:55 UTC 6182 followers, 8014 engagements


"Today we issued a safety update for our approved gene therapy. Read here:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1901979516135780640) 2025-03-18 12:50:28 UTC 6177 followers, 2930 engagements


"Today we shared updates from our clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5 2D/R3 and 2E/R4. Read more here:"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1912122376738779536) 2025-04-15 12:34:34 UTC 6173 followers, 3423 engagements


"Excited to be a partner of the 2025 @MDAorg Clinical & Scientific Conference. Well be there celebrating XX years of #MDA impact & sharing updates on how Sarepta is advancing science for Duchenne and LGMD patients. #MDAconference"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1900643260193784031) 2025-03-14 20:20:40 UTC 6181 followers, 2773 engagements


"Today we announced a licensing and collaboration agreement with Arrowhead Pharmaceuticals that will provide Sarepta with exclusive global rights to multiple clinical pre-clinical and discovery stage programs for rare genetic diseases"  
![@Sarepta Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::2216555822.png) [@Sarepta](/creator/x/Sarepta) on [X](/post/tweet/1861380714509267057) 2024-11-26 12:05:19 UTC 6182 followers, 7922 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Sarepta Avatar @Sarepta Sarepta Therapeutics

Sarepta Therapeutics posts on X about the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

  • X Week XXXXX -XX%
  • X Month XXXXXX +31%
  • X Months XXXXXX +491%
  • X Year XXXXXX -XX%

Mentions: X #

Mentions Line Chart

  • X Week XX -XX%
  • X Month XX +21%
  • X Months XX +94%
  • X Year XX +175%

Followers: XXXXX #

Followers Line Chart

  • X Week XXXXX +1.80%
  • X Month XXXXX +3.50%
  • X Months XXXXX +7.50%
  • X Year XXXXX +13%

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #


Top accounts mentioned or mentioned by @yachmod @cphilstrom @genbio @parentprojectmd @jmaraganore @alexwestchester @yasiejko @marksharkking @mdaorg @duncanburnsma @yaireinhorn @stock_truth @yusufhameed @pharmacompass @superduperdrugs @defeatduchenne @paulmarganski @cureduchenne @zinselmeyerb @rwarner42

Top Social Posts #


Top posts by engagements in the last XX hours

"News: The U.S. FDA granted Platform Technology Designation to SRP-9003 Sareptas investigational gene therapy for the treatment of LGMD type 2E/R4. This is one of the first programs to receive the technology designation. Read more at"
@Sarepta Avatar @Sarepta on X 2025-06-04 14:35:55 UTC 6182 followers, 8014 engagements

"Today we issued a safety update for our approved gene therapy. Read here:"
@Sarepta Avatar @Sarepta on X 2025-03-18 12:50:28 UTC 6177 followers, 2930 engagements

"Today we shared updates from our clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5 2D/R3 and 2E/R4. Read more here:"
@Sarepta Avatar @Sarepta on X 2025-04-15 12:34:34 UTC 6173 followers, 3423 engagements

"Excited to be a partner of the 2025 @MDAorg Clinical & Scientific Conference. Well be there celebrating XX years of #MDA impact & sharing updates on how Sarepta is advancing science for Duchenne and LGMD patients. #MDAconference"
@Sarepta Avatar @Sarepta on X 2025-03-14 20:20:40 UTC 6181 followers, 2773 engagements

"Today we announced a licensing and collaboration agreement with Arrowhead Pharmaceuticals that will provide Sarepta with exclusive global rights to multiple clinical pre-clinical and discovery stage programs for rare genetic diseases"
@Sarepta Avatar @Sarepta on X 2024-11-26 12:05:19 UTC 6182 followers, 7922 engagements

@Sarepta
/creator/twitter::Sarepta